Why Hematocrit Is Monitored During Testosterone Therapy

Written by the Innovative Men’s Health Editorial Team

Medically reviewed by Alessa Lopez-Castor, ARNP, DNP

Last medically reviewed: September 6, 2026

If you are evaluating testosterone replacement therapy (TRT), or you are already in care, your laboratory monitoring will typically include hematocrit. That single number is one of the most important safety markers clinicians watch while testosterone is prescribed.

This article explains what hematocrit measures, why testosterone can raise it, how professional guidelines approach monitoring, and what an elevated result usually prompts — always in the context of an individualized medical evaluation. It is educational only and is not a diagnosis or treatment plan.

What hematocrit measures

Hematocrit is the percentage of your blood made up of red blood cells. Those cells carry oxygen from your lungs to the rest of your body. The remaining portion of blood includes plasma, white blood cells, and platelets.

According to MedlinePlus (a service of the National Library of Medicine), a hematocrit test is often part of a complete blood count (CBC). Results that are too high or too low can relate to many conditions — from dehydration to disorders that affect red blood cell production — so interpretation always belongs with a licensed medical provider who knows your full history.

Why testosterone can raise hematocrit

Testosterone stimulates red blood cell production. FDA-approved testosterone product labeling describes increases in hematocrit that reflect increases in red blood cell mass. In some men, that rise is modest. In others, hematocrit climbs enough that clinicians pause, adjust, or further evaluate therapy.

The Endocrine Society’s 2018 clinical practice guideline on testosterone therapy in men with hypogonadism notes that testosterone administration increases hemoglobin and hematocrit, that these effects relate to dose and circulating testosterone concentrations, and that erythrocytosis (commonly defined in the guideline as hematocrit above 54%) can occur in some men. The same guideline notes that the hematocrit increase and the frequency of erythrocytosis tend to be higher in older men than in younger men.

A commissioned meta-analysis summarized in that guideline found testosterone treatment associated with a significantly higher frequency of erythrocytosis compared with placebo. That does not mean every man on TRT will develop a high hematocrit. It does mean monitoring is a standard part of responsible care.

The American Urological Association (AUA) similarly advises measuring hemoglobin and hematocrit before therapy and counseling patients about the risk of polycythemia, with intervention warranted when hematocrit is 54% or higher during treatment.

Why an elevated hematocrit matters

When red blood cell mass rises substantially, blood viscosity can increase. FDA labeling for testosterone products notes that an increase in red blood cell mass may increase the risk of thromboembolic events, and it advises clinicians to evaluate patients who develop concerning symptoms. Product labeling also references postmarketing reports of venous thromboembolism associated with testosterone products.

That caution is why hematocrit is monitored — not because any specific number automatically causes a clot. The Endocrine Society guideline states that the hematocrit level at which the risk of neuro-occlusive or cardiovascular events increases is not known, and that the frequency of such events in randomized trials among men with hypogonadism who developed erythrocytosis has been very low. Guideline thresholds of approximately 54%, depending on the applicable guideline (for example, pausing therapy when hematocrit is above 54% under Endocrine Society guidance), are clinical decision points for evaluation and management, not proof that a clot has occurred or is inevitable.

Other factors can also raise hematocrit independently of testosterone — for example dehydration, living at high altitude, certain lung or heart conditions, untreated sleep apnea, or primary blood disorders. That is one reason providers investigate contributing causes rather than looking at a single lab value in isolation.

How guidelines approach monitoring

Both FDA product labeling and Endocrine Society guidance emphasize checking hematocrit before treatment and again during therapy.

FDA labeling (representative testosterone gel prescribing information) advises:

• Check hematocrit prior to initiating treatment

• Re-evaluate hematocrit about 3 to 6 months after starting treatment, then annually

• If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable concentration

The Endocrine Society 2018 guideline recommends determining hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit is above 54%, the guideline recommends stopping therapy until hematocrit decreases to a safe level, evaluating the patient for hypoxia and sleep apnea, and reinitiating therapy at a reduced dose. Therapeutic phlebotomy is also described in the guideline as an effective option for managing testosterone treatment–induced erythrocytosis when clinically appropriate.

AUA guidance likewise calls for hemoglobin and hematocrit measurement before testosterone therapy and intervention when hematocrit is 54% or higher during treatment (for example, dose reduction or temporary discontinuation), with baseline values above 50% prompting investigation before starting therapy.

The Endocrine Society also recommends against starting testosterone therapy in men with elevated hematocrit (among other specified conditions), underscoring why a baseline CBC matters before anyone begins treatment.

Exact schedules and action thresholds can vary by product labeling, clinical context, and clinician judgment. Your provider’s monitoring plan for you may differ from another patient’s plan — and that is appropriate.

What patients can expect during monitoring

In a typical TRT pathway, hematocrit is reviewed:

1. Before starting therapy, as part of the baseline evaluation that also includes symptoms, history, and confirmatory testosterone testing when clinically indicated

2. Early after initiation, commonly in the first several months, when many lab changes become apparent

3. On an ongoing schedule, often at least annually once therapy is stable, or more often if prior values were rising or other risk factors are present

If hematocrit rises, a licensed medical provider may recommend one or more steps such as repeating labs, adjusting the treatment approach, investigating sleep apnea or other contributors, temporarily holding therapy, or coordinating additional evaluation. None of those steps is one-size-fits-all, and none should be self-directed from an article online.

At Innovative Men’s Health in Bellevue, TRT recommendations are based on symptoms, medical history, and comprehensive lab testing, with ongoing monitoring as part of care. Eligible patients throughout Washington may also access provider-guided telehealth when clinically appropriate.

Key takeaways

• Hematocrit measures the percentage of blood made up of red blood cells and is a core safety lab during testosterone therapy.

• Testosterone can increase red blood cell mass; FDA labeling, Endocrine Society guidance, and AUA guidance all support hematocrit checks before and during treatment.

• An elevated hematocrit warrants clinical attention and may lead to holding or adjusting therapy; contributing factors such as sleep apnea may also need evaluation.

• Guideline thresholds of approximately 54%, depending on the applicable guideline, are triggers for clinician-directed action, not automatic proof of clotting risk at that exact number.

• Monitoring schedules and next steps are individualized; results vary, and treatment requires an appropriate medical evaluation.

FAQs

Is a rising hematocrit on TRT always dangerous?

Not automatically. Many men experience some increase. The clinical question is whether the value crosses a threshold that requires action, whether symptoms or other risk factors are present, and what else might be contributing. That determination belongs with your provider.

Does a high hematocrit mean I have polycythemia vera?

Not necessarily. Testosterone-related erythrocytosis is typically secondary (driven by the medication and related physiology). Primary bone marrow disorders are different. Persistent, unexplained, or atypical elevations may prompt additional testing as determined by a clinician.

Why do providers also ask about sleep apnea?

Obstructive sleep apnea and hypoxia can contribute to elevated hematocrit. Endocrine Society guidance specifically recommends evaluating for hypoxia and sleep apnea when hematocrit rises above 54% during testosterone therapy.

Can lifestyle factors affect hematocrit?

Yes. Dehydration can temporarily raise hematocrit. Smoking, altitude, and certain medical conditions can also influence results. Discuss timing of labs and relevant habits with your care team so results are interpreted accurately.

Should I stop testosterone on my own if my hematocrit is high?

No. Do not start, stop, or change prescription therapy based on an article or a single lab printout. Contact your licensed medical provider promptly so they can interpret the result and advise next steps.

Next step

If you are exploring testosterone therapy — or you want a clearer conversation about lab monitoring — Innovative Men’s Health offers provider-guided evaluation in Bellevue and telehealth for eligible patients across Washington. Start with a consultation to review symptoms, history, and labs.

• Learn about testosterone">https://www.innovativehealthsolutions.net/testosterone-replacement-therapy">testosterone replacement therapy at IMHS

• Contact">https://www.innovativehealthsolutions.net/contact">Contact Innovative Men’s Health or call (425) 455-1700

Sources

1. MedlinePlus. Hematocrit Test. National Library of Medicine. https://medlineplus.gov/lab-tests/hematocrit-test/

2. Endocrine Society. Testosterone Therapy for Hypogonadism Guideline Resources (Bhasin et al., J Clin Endocrinol Metab, 2018). https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy

3. American Urological Association. Evaluation and Management of Testosterone Deficiency: AUA Guideline. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline

4. DailyMed / FDA. Testosterone gel prescribing information — Warnings and Precautions, Polycythemia. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=415057d5-8ed3-42dd-9637-05145c84a9c2&type=display

Medical disclaimer

This article is for educational purposes only and is not medical advice, diagnosis, or a treatment recommendation. Testosterone therapy is appropriate only after evaluation by a licensed medical provider, including clinically indicated laboratory testing. Eligibility, monitoring schedules, and outcomes vary. Do not start, stop, or change any medication based on this content. Seek personalized care for questions about your health.Written by the Innovative Men’s Health Editorial Team

Medically reviewed by Alessa Lopez-Castor, ARNP, DNP

Last medically reviewed: September 6, 2026

If you are evaluating testosterone replacement therapy (TRT), or you are already in care, your laboratory monitoring will typically include hematocrit. That single number is one of the most important safety markers clinicians watch while testosterone is prescribed.

This article explains what hematocrit measures, why testosterone can raise it, how professional guidelines approach monitoring, and what an elevated result usually prompts — always in the context of an individualized medical evaluation. It is educational only and is not a diagnosis or treatment plan.

What hematocrit measures

Hematocrit is the percentage of your blood made up of red blood cells. Those cells carry oxygen from your lungs to the rest of your body. The remaining portion of blood includes plasma, white blood cells, and platelets.

According to MedlinePlus (a service of the National Library of Medicine), a hematocrit test is often part of a complete blood count (CBC). Results that are too high or too low can relate to many conditions — from dehydration to disorders that affect red blood cell production — so interpretation always belongs with a licensed medical provider who knows your full history.

Why testosterone can raise hematocrit

Testosterone stimulates red blood cell production. FDA-approved testosterone product labeling describes increases in hematocrit that reflect increases in red blood cell mass. In some men, that rise is modest. In others, hematocrit climbs enough that clinicians pause, adjust, or further evaluate therapy.

The Endocrine Society’s 2018 clinical practice guideline on testosterone therapy in men with hypogonadism notes that testosterone administration increases hemoglobin and hematocrit, that these effects relate to dose and circulating testosterone concentrations, and that erythrocytosis (commonly defined in the guideline as hematocrit above 54%) can occur in some men. The same guideline notes that the hematocrit increase and the frequency of erythrocytosis tend to be higher in older men than in younger men.

A commissioned meta-analysis summarized in that guideline found testosterone treatment associated with a significantly higher frequency of erythrocytosis compared with placebo. That does not mean every man on TRT will develop a high hematocrit. It does mean monitoring is a standard part of responsible care.

The American Urological Association (AUA) similarly advises measuring hemoglobin and hematocrit before therapy and counseling patients about the risk of polycythemia, with intervention warranted when hematocrit is 54% or higher during treatment.

Why an elevated hematocrit matters

When red blood cell mass rises substantially, blood viscosity can increase. FDA labeling for testosterone products notes that an increase in red blood cell mass may increase the risk of thromboembolic events, and it advises clinicians to evaluate patients who develop concerning symptoms. Product labeling also references postmarketing reports of venous thromboembolism associated with testosterone products.

That caution is why hematocrit is monitored — not because any specific number automatically causes a clot. The Endocrine Society guideline states that the hematocrit level at which the risk of neuro-occlusive or cardiovascular events increases is not known, and that the frequency of such events in randomized trials among men with hypogonadism who developed erythrocytosis has been very low. Guideline thresholds of approximately 54%, depending on the applicable guideline (for example, pausing therapy when hematocrit is above 54% under Endocrine Society guidance), are clinical decision points for evaluation and management, not proof that a clot has occurred or is inevitable.

Other factors can also raise hematocrit independently of testosterone — for example dehydration, living at high altitude, certain lung or heart conditions, untreated sleep apnea, or primary blood disorders. That is one reason providers investigate contributing causes rather than looking at a single lab value in isolation.

How guidelines approach monitoring

Both FDA product labeling and Endocrine Society guidance emphasize checking hematocrit before treatment and again during therapy.

FDA labeling (representative testosterone gel prescribing information) advises:

• Check hematocrit prior to initiating treatment

• Re-evaluate hematocrit about 3 to 6 months after starting treatment, then annually

• If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable concentration

The Endocrine Society 2018 guideline recommends determining hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit is above 54%, the guideline recommends stopping therapy until hematocrit decreases to a safe level, evaluating the patient for hypoxia and sleep apnea, and reinitiating therapy at a reduced dose. Therapeutic phlebotomy is also described in the guideline as an effective option for managing testosterone treatment–induced erythrocytosis when clinically appropriate.

AUA guidance likewise calls for hemoglobin and hematocrit measurement before testosterone therapy and intervention when hematocrit is 54% or higher during treatment (for example, dose reduction or temporary discontinuation), with baseline values above 50% prompting investigation before starting therapy.

The Endocrine Society also recommends against starting testosterone therapy in men with elevated hematocrit (among other specified conditions), underscoring why a baseline CBC matters before anyone begins treatment.

Exact schedules and action thresholds can vary by product labeling, clinical context, and clinician judgment. Your provider’s monitoring plan for you may differ from another patient’s plan — and that is appropriate.

What patients can expect during monitoring

In a typical TRT pathway, hematocrit is reviewed:

1. Before starting therapy, as part of the baseline evaluation that also includes symptoms, history, and confirmatory testosterone testing when clinically indicated

2. Early after initiation, commonly in the first several months, when many lab changes become apparent

3. On an ongoing schedule, often at least annually once therapy is stable, or more often if prior values were rising or other risk factors are present

If hematocrit rises, a licensed medical provider may recommend one or more steps such as repeating labs, adjusting the treatment approach, investigating sleep apnea or other contributors, temporarily holding therapy, or coordinating additional evaluation. None of those steps is one-size-fits-all, and none should be self-directed from an article online.

At Innovative Men’s Health in Bellevue, TRT recommendations are based on symptoms, medical history, and comprehensive lab testing, with ongoing monitoring as part of care. Eligible patients throughout Washington may also access provider-guided telehealth when clinically appropriate.

Key takeaways

• Hematocrit measures the percentage of blood made up of red blood cells and is a core safety lab during testosterone therapy.

• Testosterone can increase red blood cell mass; FDA labeling, Endocrine Society guidance, and AUA guidance all support hematocrit checks before and during treatment.

• An elevated hematocrit warrants clinical attention and may lead to holding or adjusting therapy; contributing factors such as sleep apnea may also need evaluation.

• Guideline thresholds of approximately 54%, depending on the applicable guideline, are triggers for clinician-directed action, not automatic proof of clotting risk at that exact number.

• Monitoring schedules and next steps are individualized; results vary, and treatment requires an appropriate medical evaluation.

FAQs

Is a rising hematocrit on TRT always dangerous?

Not automatically. Many men experience some increase. The clinical question is whether the value crosses a threshold that requires action, whether symptoms or other risk factors are present, and what else might be contributing. That determination belongs with your provider.

Does a high hematocrit mean I have polycythemia vera?

Not necessarily. Testosterone-related erythrocytosis is typically secondary (driven by the medication and related physiology). Primary bone marrow disorders are different. Persistent, unexplained, or atypical elevations may prompt additional testing as determined by a clinician.

Why do providers also ask about sleep apnea?

Obstructive sleep apnea and hypoxia can contribute to elevated hematocrit. Endocrine Society guidance specifically recommends evaluating for hypoxia and sleep apnea when hematocrit rises above 54% during testosterone therapy.

Can lifestyle factors affect hematocrit?

Yes. Dehydration can temporarily raise hematocrit. Smoking, altitude, and certain medical conditions can also influence results. Discuss timing of labs and relevant habits with your care team so results are interpreted accurately.

Should I stop testosterone on my own if my hematocrit is high?

No. Do not start, stop, or change prescription therapy based on an article or a single lab printout. Contact your licensed medical provider promptly so they can interpret the result and advise next steps.

Next step

If you are exploring testosterone therapy — or you want a clearer conversation about lab monitoring — Innovative Men’s Health offers provider-guided evaluation in Bellevue and telehealth for eligible patients across Washington. Start with a consultation to review symptoms, history, and labs.

• Learn about testosterone replacement therapy at IMHS

• Contact Innovative Men’s Health or call (425) 455-1700

Sources

1. MedlinePlus. Hematocrit Test. National Library of Medicine. https://medlineplus.gov/lab-tests/hematocrit-test/

2. Endocrine Society. Testosterone Therapy for Hypogonadism Guideline Resources (Bhasin et al., J Clin Endocrinol Metab, 2018). https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy

3. American Urological Association. Evaluation and Management of Testosterone Deficiency: AUA Guideline. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline

4. DailyMed / FDA. Testosterone gel prescribing information — Warnings and Precautions, Polycythemia. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=415057d5-8ed3-42dd-9637-05145c84a9c2&type=display

Medical disclaimer

This article is for educational purposes only and is not medical advice, diagnosis, or a treatment recommendation. Testosterone therapy is appropriate only after evaluation by a licensed medical provider, including clinically indicated laboratory testing. Eligibility, monitoring schedules, and outcomes vary. Do not start, stop, or change any medication based on this content. Seek personalized care for questions about your health.